Indication
Carcinoid Syndrome
4 clinical trials
6 products
Product
PaltusotineClinical trial
A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects With Carcinoid SyndromeStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid SyndromeStatus: Completed, Estimated PCD: 2013-05-01
Product
PlaceboProduct
LanreotideClinical trial
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NET-PACS Trial) Big Ten Cancer Research Consortium BTCRC-GI19-400Status: Withdrawn, Estimated PCD: 2023-02-01
Product
TelotristatClinical trial
Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PETStatus: Recruiting, Estimated PCD: 2023-10-01
Product
Telotristat Etiprate